Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment

CONCLUSIONS: Resistant gene mutations caused by anti-EGFR drugs in RAS/BRAF wild-type mCRC patients can be observed by dynamic ctDNA analysis. TP53 and AMER1 mutations, tumor mutational burden (TMB) levels, and TP53/AMER1 co-mutation may predict the efficacy of the first-line cetuximab-contained treatment. Situations of genetic mutations were differentiated from first-line PD to second-line PD, which indicated that mutation detection may contribute to predict prognosis of mCRC patients.PMID:38503018 | DOI:10.1016/j.intimp.2024.111887

Source: International Immunopharmacology - March 19, 2024 Category: Allergy & Immunology Authors: Yu-Wen Zhou Xin Zhao Lu Ni Peng Cao Wei-Bing Leng Qing Zhu Hong-Feng Gou Jiao Zhang Xiao-Fen Li Meng Qiu Source Type: research